Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Google Secures Pentagon AI Deal for Classified Projects 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
DURHAM, N.C., Feb. 16, 2016 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that detailed results from the Company’s Phase 3 SUPPRESS trial of brincidofovir in patients undergoing hematopoietic cell transplantation (HCT), will be presented at the BMT Tandem Meetings in Honolulu, Hawaii. The presentation will be held on Saturday, February 20, 2016 at 4:00 p.m. HST (9:00 p.m. EST) at the Hawaii Convention Center in Honolulu, Hawaii. Presentation slides will be posted to the Chimerix website following the conclusion of the presentation.
Chimerix’s management team will host a live conference call and webcast at 8:00 a.m. EST on Monday, February 22, 2016 to discuss the SUPPRESS trial results as well as provide an update on the brincidofovir clinical program. To access the live conference call, please dial 877-354-4056 (domestic) or 678-809-1043 (international) at least five minutes prior to the start time and refer to conference ID 52881232.
A live webcast of the call and accompanying slides will also be available on the Investors’ section of the Company’s website, www.chimerix.com and an archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (CMX001), a clinical-stage nucleotide analog, CMX157 which was licensed to ContraVir Pharmaceuticals in 2014, and early clinical candidates including CMX669. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Jesse Baumgartner Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
